Next Financial Group’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Next Financial Group’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-681	Closed	-$15K	–	2380
2016 Q3	$15K	Buy	+681	New	+$14K	﹤0.01%	1472
2016 Q1	–	Sell	-204	Closed	-$5K	–	1724
2015 Q4	$5K	Hold	204	–	–	﹤0.01%	1365
2015 Q3	$5K	Buy	+204	New	+$6.9K	﹤0.01%	1403

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCP

Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

MFS

MSI Financial Services Springfield, Massachusetts $3.07B AUM 10.22% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Next Financial Group's BBC Position: Q4 2016 in Review

Next Financial Group sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q4 2016, closing a stake of 681 shares — an estimated $15K sold.

Next Financial Group first reported a position in BBC in Q3 2015 and held it in 3 quarters. The position peaked at $15K in Q3 2016. 16 funds tracked by Wall St. Rank hold BBC as of Q4 2016.

Next Financial Group reported no remaining Virtus Biotech Clinical Trials ETF position as of Q4 2016 after selling out during the quarter.
Next Financial Group sold 681 Virtus Biotech Clinical Trials ETF shares in Q4 2016, an estimated $15K.
Next Financial Group first reported a position in Virtus Biotech Clinical Trials ETF in Q3 2015 and held it in 3 quarters.
Next Financial Group's Virtus Biotech Clinical Trials ETF position peaked at $15K in Q3 2016.
16 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q4 2016.

Based on Next Financial Group's 13F filing for Q4 2016, filed 2 Feb 2017.